Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637222 | 1.00 | HTR1B (0.48) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL1880414 | 0.86 | HTR1B (0.50) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL2022643 | 0.80 | KMT2A (0.39) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL2022641 | 0.80 | KMT2A (0.39) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL2023871 | 0.79 | MEN1 (0.38) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL2023870 | 0.79 | MEN1 (0.38) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL3155776 | 0.79 | HTR1B (0.63) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL14624162 | 0.79 | HTR1B (0.55) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL1874230 | 0.77 | HTR1B (0.50) | HTR1BHTR1AHTR1DKMT2AMEN1 | |
| SCHEMBL16026816 | 0.72 | HTR1B (0.62) | HTR1BHTR1AHTR1DKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935722-B2 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | HTR1B 1072/4885HTR1A 1299/4885HTR1D 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.